Inherited sodium channelopathies: Novel therapeutic and proarrhythmic molecular mechanisms

Trends in Cardiovascular Medicine

Volumn 11, Issue 6, 2001, Pages 229-237

  Balser, Jeffrey R ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; FLECAINIDE; LIDOCAINE; PROCAINAMIDE; SODIUM CHANNEL; SODIUM CHANNEL AFFECTING AGENT; SODIUM CHANNEL BLOCKING AGENT;

BRUGADA SYNDROME; CHANNEL GATING; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HEART RATE; HEART RHYTHM; HUMAN; LONG QT SYNDROME; MEMBRANE POTENTIAL; MUTATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW;

ARRHYTHMIA; HUMANS; LONG QT SYNDROME; SODIUM CHANNEL BLOCKERS; SODIUM CHANNELS;

EID: 0034756658     PISSN: 10501738     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1050-1738(01)00116-5     Document Type: Review

References (61)

1. Molecular pharmacology of the sodium channel mutation D1790G linked to the long-QT syndrome
2. 'Brugada' syndrome; clinical data and suggested pathophysiological mechanism
3. Lidocaine block of LQT-3 mutant human Na channels
4. Novel LQT-3 mutation affects Na+ channel activity through interactions between alpha- and beta1-subunits
5. Functional consequences of lidocaine binding to slow-inactivated sodium channels
6. SCN5A mutation (T1620M) causing Brugada syndrome exhibits different phenotypes when expressed in Xenopus oocytes and mammalian cells
7. Use-dependent blockers and exit rate of the last ion from the multi-ion pore of a K channel
8. Effects of flecainide in patients with new SCN5A mutation; mutation-specific therapy for long-QT syndrome?
9. Molecular mechanism for an inherited cardiac arrhythmia
10. A single Na(+) channel mutation causing both long-QT and Brugada syndromes
11. Right bundle branch block, persistent ST segment elevation and sudden cardiac death; a distinct clinical and electrocardiographic syndrome. A multicenter report
12. Voltage sensors in domains III and IV, but not I and II, are immobilized by Na+ channel fast inactivation
13. Genetic basis and molecular mechanism for idiopathic ventricular fibrillation
14. Lidocaine induces a slow inactivated state in rat skeletal muscle sodium channels
15. Linking a genetic defect to its cellular phenotype in a cardiac arrhythmia
16. Mechanism of frequency-dependent inhibition of sodium currents in the frog myelinated nerve by the lidocaine derivative gea 968
17. Electrophysiological characterization of SCN5A mutations causing long QT (E1784K) and Brugada (R1512W and R1432G) syndromes
18. Ionic mechanisms responsible for the electrocardiographic phenotype of the Brugada syndrome are temperature dependent
19. Multiple mechanisms of Na+ channel-linked long-QT syndrome
20. Mortality and morbidity in patients receiving encainide, flecainide, or placebo
21. ST segment elevation in the right precordial leads induced with class IC antiarrhythmic drugs; insight into the mechanism of Brugada syndrome
22. Local anesthetics; hydrophilic and hydrophobic pathways for the drug-receptor reaction
23. A quantitative description of membrane current and its application to conduction and excitation in nerve
24. Time- and voltage-dependent interactions of the antiarrhythmic drugs with cardiac sodium channels
25. Sodium channels need not open before they inactivate
26. Mechanistic link between local anesthetic action and inactivation gating probed by outer pore mutations in the rat μ1 sodium channel
27. Phenotypic characterization of a novel long QT syndrome mutation in the cardiac sodium channel
28. A revised view of cardiac sodium channel blockade in the long-QT syndrome
29. Electrophysiological properties and responses to simulated ischemia in cat ventricular myocytes of endocardial and epicardial origin
30. Sodium channel block produces opposite electrophysiological effects in canine ventricular epicardium and endocardium
31. Flecainide-induced arrhythmia in canine ventricular epicardium
32. Differences in the electrophysiological response of canine ventricular epicardium and endocardium to ischemia; role of the transient outward current
33. A dynamic model of the cardiac ventricular action potential. I. Simulations of ionic currents and concentration changes
34. Autonomic and antiarrhythmic drug modulation of ST segment elevation in patients with Brugada syndrome
35. Isoform-specific lidocaine block of sodium channels explained by differences in gating
36. A structural rearrangement in the sodium channel pore linked to slow inactivation and use dependence
37. The elusive link between LQT3 and Brugada syndrome; the role of flecainide challenge
38. Lidocaine action on Na+ currents in ventricular myocytes from the epicardial border zone of the infarcted heart
39. Alterations of Na+ currents in myocytes from epicardial border zone of the infarcted heart. A possible ionic mechanism for reduced excitability and postrepolarization refractoriness
40. Molecular determinants of state-dependent block of Na+ channels by local anesthetics
41. Common molecular determinants of local anesthetic, antiarrhythmic, and anticonvulsant block of voltage-gated Na+ channels
42. Drug-induced J point elevation; a marker for genetic risk of sudden death or ECG curiosity?
43. Human SCN5A gene mutations alter cardiac sodium channel kinetics and are associated with the Brugada syndrome
44. Slow inactivation of the sodium conductance in squid giant axons. Pronase resistance
45. Cardiac conduction defects associate with mutations in SCN5A
46. Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy
47. Sodium channel block with mexilitine is effective in reducing dispersion of repolarization and preventing torsade de pointes in LQT2 and LQT3 models of the long-QT syndrome
48. Sodium channel selectivity filter regulates antiarrhythmic drug binding
49. A sodium channel mutation causes isolated cardiac conduction disease
50. The position of the fast-inactivation gate during lidocaine block of voltage-gated Na+ channels
51. Two distinct congenital arrhythmias evoked by a multidysfunctional Na(+) channel
52. A molecular mechanism for class IA drug intolerance in the Brugada syndrome
53. Enhanced sodium channel intermediate inactivation in Brugada syndrome
54. Characterization of human cardiac Na+ channel mutations in the congenital long QT syndrome
55. Pharmacological targeting of long QT mutant sodium channels
56. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome
57. Sodium channel abnormalities are infrequent in patients with long QT syndrome; identification of two novel SCN5A mutations
58. Congenital long-QT syndrome caused by a novel mutation in a conserved acidic domain of the cardiac Na+ channel
59. A cluster of hydrophobic amino acid residues required for fast Na+-channel inactivation
60. Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST-segment elevation
61. Evidence for voltage-dependent S4 movement in sodium channels